Baozun does e-commerce tools

Some of China’s top technology leaders are set to attend a symposium next week chaired by President Xi Jinping, Reuters reported, providing a potential confidence boost for the country’s private sector. Top tech executives likely to attend the event, which could happen on Monday, include Alibaba co-founder Jack Ma, Tencent Chairman Pony Ma and Lei Jun, co-founder and CEO of smartphone maker Xiaomi, according to the report, citing unnamed sources.

The symposium aims to boost sentiment among executives in China’s private sector, and Xi is expected to encourage participants to expand their businesses both domestically and internationally, according to the report.

China has engaged in a series of crackdowns in recent years against many industries dominated by private companies, leading many to feel that Xi favors state-run firms over private ones. The number of crackdowns has dropped off in the last two years as the government turns its focus to supporting the nation’s slowing economy, though anti-corruption campaigns continue in some areas like the pharmaceutical industry.

By Doug Young

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…